A clinical study from the University of Calgary accelerates stroke treatment
A Canadian-led clinical study has established a new global standard for treating ischemic strokes by replacing the hour-long infusion of alteplase with a five‑second injection of tenecteplase. The tenecteplase regimen was shown to be equally effective and safe in the AcT trial conducted by the University of Calgary. The simplified administration allows healthcare providers to focus more on patients and enables rapid treatment in remote areas, including small hospitals and ambulances. The research team achieved regulatory approval from major agencies, including the FDA, marking a milestone for the Calgary Stroke Program and demonstrating the strength of academically driven medical innovation.

Estilo de reportagemFactual
Primarily factual reporting on medical research and regulatory approvals








